A Phase 1 Clinical Trial to Evaluate Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 06 Aug 2018 Planned End Date changed from 1 Jul 2028 to 1 Aug 2028.
- 06 Aug 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020.
- 06 Aug 2018 Status changed from not yet recruiting to recruiting.